LEADER 01380oam  2200409Ia 450 
001 9910699117703321
005 20230902162211.0
035   $a(CKB)5470000002400722
035   $a(OCoLC)465469950
035   $a(EXLCZ)995470000002400722
100   $a20091113d2009      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $epharmaceutical components at risk for melamine contamination
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Veterinary Medicine,$d[2009]
215   $a1 online resource (5 pages)
300   $a"Current Good Manufacturing Practice (CGMP)."
300   $a"August 2009."
517   $aGuidance for industry 
606   $aDrug adulteration
606   $aMelamine
606   $aVeterinary drug residues
615  0$aDrug adulteration.
615  0$aMelamine.
615  0$aVeterinary drug residues.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Veterinary Medicine (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910699117703321
996   $aGuidance for industry$93434577
997   $aUNINA